Skip to main content
TipRanks
Go Ultimate75% OFF

SELLAS Life Sciences Group (RXK3) Stock Price & Analysis

2 Followers

RXK3 Stock Chart & Stats

€18.65€11.63(165.67%)
At close: 5:30 PM GMT+1
€10€15Aug 25Sep 7Sep 24Oct 2Oct 21Nov 2Nov 16
Day’s Range
EUR 6.88 - EUR 18.65
52-Week Range
EUR 1.20 - EUR 18.65
Previous Close
EUR 7.02
Volume
N/A
Average Volume (3M)
987
Market Cap
EUR 3.55B
Enterprise Value
EUR 2.36B
Total Cash (Recent Filing)
EUR 134.71M
Total Debt (Recent Filing)
EUR 599.00K
Price to Earnings (P/E)
―
Beta
0.44
Next Earnings
Mar 25, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Phase 3 REGAL Validation And Regulatory Path

The positive Phase 3 result materially strengthens GPS’s clinical credibility, with a statistically significant survival benefit and no new safety signals. Planned FDA engagement and BLA preparation create a defined regulatory path that could move the lead program toward commercialization.

Multiple Oncology Immunotherapy Programs

A pipeline spanning GPS and NPS gives SELLAS more than one potential clinical value driver and applies its immunotherapy approach across different cancer settings. This diversification can support longer-term strategic flexibility if individual indications develop unevenly.

Low Leverage And Stronger Equity Capitalization

Minimal debt reduces refinancing pressure and fixed financial obligations, while the improvement in equity capitalization strengthens solvency relative to prior periods. This gives SELLAS more balance-sheet flexibility to fund clinical and regulatory work than a highly leveraged structure would.

Bears Say

Pre-revenue Business Model

SELLAS has no established commercial revenue base to absorb research, development, and corporate costs. Until a candidate is approved and launched, operating performance remains dependent on clinical progress and external capital rather than recurring product sales.

Persistent Cash Burn And Funding Needs

Continued negative operating and free cash flow means SELLAS must keep financing operations while advancing its programs. Persistent cash consumption can constrain strategic choices and require additional capital before potential product revenue becomes available.

Dependence On Equity Financing

The company’s large equity offering highlights ongoing reliance on capital markets to support development before commercialization. Issuing additional shares can dilute existing ownership and leaves future funding capacity exposed to the need for repeated financing.

SELLAS Life Sciences Group News

RXK3 FAQ

What was SELLAS Life Sciences Group’s price range in the past 12 months?
SELLAS Life Sciences Group lowest stock price was €1.20 and its highest was €18.65 in the past 12 months.
What is SELLAS Life Sciences Group’s market cap?
SELLAS Life Sciences Group’s market cap is €3.55B.
When is SELLAS Life Sciences Group’s upcoming earnings report date?
SELLAS Life Sciences Group’s next earnings report is estimated for Mar 25, 2027 (not yet confirmed), which is in 127 days.
How were SELLAS Life Sciences Group’s earnings last quarter?
SELLAS Life Sciences Group released its earnings results on Nov 12, 2026. The company reported -€0.045 earnings per share for the quarter.
Is SELLAS Life Sciences Group overvalued?
According to Wall Street analysts SELLAS Life Sciences Group’s price is currently Undervalued.
Does SELLAS Life Sciences Group pay dividends?
SELLAS Life Sciences Group does not currently pay dividends.
What is SELLAS Life Sciences Group’s EPS estimate?
SELLAS Life Sciences Group’s EPS estimate is -0.05.
How many shares outstanding does SELLAS Life Sciences Group have?
SELLAS Life Sciences Group has 203,859,150 shares outstanding.
What happened to SELLAS Life Sciences Group’s price movement after its last earnings report?
SELLAS Life Sciences Group reported an EPS of -€0.045 in its last earnings report. Following the earnings report the stock price went down -0.533%.
Which hedge fund is a major shareholder of SELLAS Life Sciences Group?
Hedge funds hold SELLAS Life Sciences Group shares: hedge funds increased their holdings by 88.2K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology